proteomic changes upon treatment with semaglutide in individuals with obesity Suboptimal therapeutic responses associated type 2 diabetes and obesity: Semaglutide-Mediated Remodeling of Adipose Tissue

Generally appropriate for: Adults with a BMI over 27 who want to lose weight People who have struggled with appetite control Those looking for sustainable, medically-supervised weight loss Generally not appropriate if: Pregnant or breastfeeding individuals People with a personal or family history of thyroid cancer Those with multiple endocrine neoplasia syndrome (MEN 2) Individuals with diabetic retinopathy (certain eye conditions) Common side effects: Nausea (especially at the start, usually improves) Loss of appetite (expected and therapeutic) Mild constipation or diarrhea Occasional headache or dizziness These typically subside as your body adjusts Individual results vary

( G ) Schematic showing hepatic GSH depletion by Chac1 overexpression protects from MASLD through selective protein oxidation and transcriptional regulation

JACC Clin Electrophysiol

03 Where is my data stored